Talha, a visionary technology leader with over 14 years of experience, is on a mission to solve customer problems through cutting-edge technology. He has track record of of managing large enterprise product portfolios and launching successful B2B and B2C products in Aviation and Telco domains. He has demonstrated expertise in scaling teams and navigating the challenges of transitioning from a local mindset to a global market where the products he oversees reach over 20+ countries and 40+ enterprise customers worldwide.
In his dynamic career, which spans roles at TAV Technologies, Turkcell, and Huawei Technologies, Talha continues to leave a lasting impact at the crossroads of technology, product management, and leadership. His ability to unite teams around a shared vision is evident in his success in leading and expanding global teams of 30+ members across 10+ countries. His leadership principles are centered on customer-centricity, fostering creativity, and the crucial balance of trusting instincts while rigorously testing against data and feedback. As he navigates the ever-evolving landscape of technology and business, Talha remains dedicated to making a significant and positive influence on the organizations he touches.
Dr. Michael Schlattau joined Zurich-based ECOFIN Software and Technology AG – the
company that develops Finfox – in 2019 and has been Head of Business Consulting since
2021. Prior to that he worked as a research assistant at the Chair of International Management
at the University of the Bundeswehr Munich and as a senior consultant at EY in Munich.
Michael holds a degree in Business Administration from the University of Augsburg (Dipl.-
Kfm.) and earned his doctorate at the University of the Bundeswehr Munich. He was a visiting
scholar at Columbia University in New York and at the Higher School of Economics in
Moscow.
Henk Streefkerk is a physician scientist (MD PhD) with clinical experience in Ear- / Nose- / Throat surgery and a PhD in Neurovascular surgery. Working experience is both in big pharma (>10 years) and bio-tech (>5 years). Henk started his pharma career as a clinical pharmacologist at Organon and Actelion. He then be-came a Translational Medicine Expert at Novartis. After moving into senior safety role, he first led the safety-related aspects of the global marketing authorization application of a heart failure drug (Entresto), followed by the same for a breast cancer drug (Kisqali). At PIQUR, as Chief Medical Officer, he led the global Clinical Development Team to manage 8 global clinical studies in various stages using a Pi3K/mTor inhibitor (bimiralisib). In view of existing quality and budget constraints, Henk has re-structured the clinical and safety departments of various biotech companies, successfully passing health authority inspections (SwissMedic / ANSM) after setting up the clinical and safety modules of the quality system. He is a co-founder of a MedTech company (Rivia.ch) which develops and commercializes software to support keeping medical oversight of clinical trials. He also setup the quality management system and information security management system according to ISO 9001 and ISO 27001/GDPR. Henk founded his own consultancy company (Streefkerk Life Sciences Consultancy), providing CMO-, Medical Director-, and Drug Safety Officer services to small biotech companies in Europe and in the USA, and is currently working as CEO of Amarna Therapeutics BV, a preclinical gene therapy company in the Netherlands.
Juliette joined Syneos Health in 2015 and is an executive leader who has 30+ years Industry Experience of which 15 years Oncology and 7 years Early Phase Oncology Focus She is also spent 11 years in Early Phase Healthy Volunteers
Juliette has spent the last 7 years providing Executive Leadership executive oversight for Global Project Delivery as well as Strategic Proposal Development and Therapeutic Adviser.
A major part of Juliette’s role is to foster Customer Relations and Alliances, consulting closely with biotechnology and pharmaceutical companies on clinical development plan design and protocol development.
Juliette holds a first degree in Psychology, a post graduate diploma in Organizational Psychology, is Six- Sigma green belt trained, a Tavistock trained Executive Coach and PMP certified
Juliette is currently heading up the Oncology Therapeutic Strategy and Innovation (TSI) leading a team of therapeutic experts in support of achieving key business objectives of the Oncology Business Unit. As TSI global head, she supports the Therapeutic Area Head in achieving growth targets by ensuring effective, customer-centric solutions are presented to customers in the Request For Proposal process.
